

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

VOLUNTARY ANNOUNCEMENT CERTIFICATION BY NMPA

This announcement is made by AK Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company obtained the certification for the unicompartamental knee prosthesis Class III medical devices approved by the National Medical Products Administration (“**NMPA**”) of the People’s Republic of China (the “**PRC**”) on 11 July 2022.

The unicompartamental knee prosthesis of the Group approved by NMPA comprises both flexible platform uni-condyle and fixed platform uni-condyle which is applicable for both medial and lateral knee abrasions. It provides full coverage for all patient suitable for uni-condylar surgery, and is the first highly cross-linked, dual system solution for uni-condylar surgery in the PRC. Compared with similar products currently available, the bone interface of the Group’s uni-condylar knee prosthesis is equipped with titanium spray layer as standard, which enhances the bone cement fixation effect and reduces the loosening rate of the prosthesis; the friction interface of the prosthesis is equipped with high cross-linked super wear-resistant gaskets as standard which, having such excellent bone interface and friction interface, can effectively improve the service life of the prosthesis and benefit more patients with uni-condylar replacement.

As a leader in the domestic orthopaedic industry, the Group continues to innovate in research and development to lead the development of domestic artificial knee joints. Since the launch of the first domestic knee joint product in 2004, the Group has been making breakthroughs in its technology, offering a complete solution from primary to revision. The Group has the largest share of all brands in the national volume-based procurement of artificial joints and has the largest user group of doctors. The obtainment of this certification for the unicompartamental knee prosthesis marks the completion of the Group’s comprehensive layout in the field of artificial knee joint prosthesis and further expansion of its market share in the knee joint is expected in the future.

At the same time, the Group has also obtained the certification for the bone filling biomaterials Class III medical devices approved by the NMPA on 5 July 2022, applicable for the field of maxillofacial surgery. The approval of this product will enable the Group to explore new business areas in the future.

By Order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Beijing, 14 July 2022

As at the date of this announcement, the executive directors are Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong; the non-executive director is Dr. Wang David Guowei; and the independent non-executive directors are Mr. Kong Chi Mo and Dr. Li Shu Wing David and Mr. Eric Wang.